A $20 million philanthropic gift from Emilia Fazzalari will enable New York-Presbyterian to establish dedicated women’s health centers across Manhattan and Westchester, with a focus on perimenopause and menopause. This move marks a significant milestone in improving clinical access and comprehensive care.
"We have rethought and reorganized women’s care in a meaningful way. This model brings a new standard to women’s health.”
— Emilia Fazzalari, Entrepreneur and Philanthropist
Pomelo Care has closed a $92 million Series C round at a $1.7 billion valuation, backing its mission to scale a proven care model beyond maternity into broader women’s and children’s health with integrated primary care and support services.
"With this funding, we're taking [our] proven model beyond maternity to build a system of care that supports women and children throughout their lives, delivering betterresults across the entire healthcare ecosystem
— Marta Bralic Kerns, founder & CEO, Pomelo Care
A major update to federal women’s health preventive guidance will make it easier for women to get screened for cervical cancer, including a self-collection option that allows some women to test themselves at home, supporting earlier and more comprehensive screening to improve early detection and reduce mortality.
“The addition of self-collection really empowers women to make this choice for themselves.... We do retain the option for Pap smear … this is just an additional choice for women."
— Ann Sheehy, MD, Chief Medical Officer, Health Resources and Services Administration
Copenhagen-based Bactolife closed more than €30 million in Series B financing to bring its Binding Proteins platform to market, advancing solutions that strengthen the human microbiome and help address antimicrobial resistance.
“This funding will enable us to clinically validate, scale, and commercialise our Binding Proteins, taking Bactolife’s solutions to a broad audience."
— Sebastian Søderberg, CEO, Bactolife
At CES 2026, Noul debuted its AI-based miLab™ CER automated cervical cancer diagnostic tool, designed to expand healthcare access and support consistent screening anywhere in the world.
"By enabling consistent cervical cancer diagnostics anywhere in the world, we aim to advance global health equity while leading a shift toward more consumer-centric diagnostic models."
— David Lim, CEO, Noul
Organon’s Accelerator Program is now open for applications, inviting innovators working on cutting-edge therapeutics for gynecological conditions, maternal health, contraception, and menopause to receive up to six months of tailored scientific and strategic guidance from Organon’s internal R&D experts, including support on clinical strategy, regulatory planning and market access.
Apply by February 19, 2026 to join the next cohort.
🔗 https://accelerateinnovation.organon.com/
